ArticleFrontiers in cellular and infection microbiology2025
Molecular and epidemiological characterization of carbapenem-resistant hypervirulent
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Molecular Epidemiology ofMicroorganisms · 2026Article
- Molecular Epidemiological Analysis of Carbapenem-Resistant Hypervirulent Klebsiella Pneumoniae in Cangzhou Central Hospital from 2021 to 2024.Pakistan journal of medical sciences · 2026Article
- High prevalence of fosfomycin resistance among ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae isolates in a tertiary hospital from Jiangxi Province, South China.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Epidemiological and genomic profiles of NDM-1-Producing ST25-KL2 carbapenem-resistant Klebsiella pneumoniae among pediatric patients in Hangzhou, China.BMC microbiology · 2026Article
- Antimicrobial resistance trends among dominant pathogens in six clinical departments of the Fourth Affiliated Hospital of Guangxi Medical University, 2020-2024.Frontiers in public health · 2026Article
- Antimicrobial Resistance, Molecular Epidemiology, and Virulence Profiles of Hypervirulent Carbapenem-ResistantInfection and drug resistance · 2026Article
- Comparative Genomic and Resistance Analysis of ST859-KL19 and ST11 Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Multicenter Surveillance ofInfection and drug resistance · 2026Article
- Spread of ST11-O13/KL47 hypervirulent carbapenem-resistant Klebsiella pneumoniae isolates in China.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Carbapenem-resistant hypervirulent Methods: We retrospectively studied patients infected with carbapenem-resistant Results: Among them, 57.49% (215/374) strains met the criteria for CR-hvKP. The most common type was blaKPC-2-producing ST11(98.60%, 212/215), whereas K64 (56.74%, 122/215) and KL25 (39.53%, 85/215) were the main capsular serotypes. The CR-hvKP strains showed significantly higher resistance to the tested antibiotics, except for ceftazidime/avibactam and colistin. Resistance rates of CR-hvKP to the three tested antibiotics (minocycline, cotrimoxazole, and amikacin) were higher than those of CRnon-hvKP. Phylogenetic analysis based on whole-genome single-nucleotide polymorphisms divided the 251 isolates into four independent branches, with branch 2 being the most prevalent, indicating high clonality among the strains. Multivariate analysis showed diabetes [odds ratio (OR) = 3.771] and surgery (OR =2.042) to be independent variables associated with CR-hvKP infection. Conclusions: Notably, the ST11 lineage carrying blaKPC-2 has emerged as a dominant high-risk clone in Huaian. Given the wide distribution of these novel CR-hvKP isolates, global monitoring and stricter control measures should be implemented to prevent their further spread in hospital settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.